OLOskar Ljungquist

Oskar Ljungquist

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oskar Ljungquist has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Blood culture time to positivity corrected for delayed incubation start - a population-based study

    by Karl Oldberg, Torgny Sunnerhagen, Oskar Ljungquist, Magnus Rasmussen, Jonas Tverring, Gustav Torisson

    Purpose: A short blood culture time to positivity (TTP) is associated with an increased risk for death in blood stream infections (BSI). However, TTP is also shortened when the time elapsed from sampling to incubation start (TTI) increases. We aimed to test whether TTP corrected for TTI was more strongly associated with 7-day mortality in BSI. Methods: This was a retrospective analysis of positive blood culture bottles in Skåne region, Sweden, 2015 to 2023, with linked clinical data obtained from healthcare databases. Correction factors were derived using linear regression between TTI and TTP. The association between TTP and 7-day mortality was studied in BSI episodes, using non-linear logistic regression. Actual mortality rates and odds ratios (OR) for different TTP cutoffs were calculated. Results: In total, 100,829 bottles were included and each hour of TTI was associated with a shortening of TTP by 0.27 h in aerobic bottles and 0.32 h in anaerobic bottles. After deduplication, 31,723 unique BSI episodes were included in mortality analysis, with a 7-day mortality rate of 6.4%. In non-linear regression models, corrected TTP showed a stronger association with 7-day mortality than crude TTP in episodes with TTP < 10 h. Actual mortality rates were higher for corrected TTP at all cutoffs between 6 and 12 h. Conclusion: TTP corrected for TTI was more strongly associated with 7-day mortality than crude TTP. We recommend that correction for TTI should be used in future studies on TTP, especially if on-site incubation is unavailable.

  • Open Access

    Etiology and Outcomes of Bloodstream Infections by Immunosuppression Type: A Population-Based Laboratory Surveillance Study

    by Oskar Ljungquist, Fredrik Resman, Karl Oldberg, Anna Bläckberg, Torgny Sunnerhagen, Gustav Torisson

    Background: An increasing proportion of the population receives immunosuppressive treatment. There is a lack of guidelines for bloodstream infections (BSIs) in this group. This study aims to provide a comprehensive analysis of the etiology and outcomes in BSI associated with underlying immunosuppression. Methods: This population-based laboratory surveillance study included all positive blood cultures in southern Sweden, from 2013 through 2023. Immunosuppression was defined using diagnostic codes, medications, and laboratory data. We defined 6 categories of immunosuppression: antineoplastic treatment, neutropenia, immunosuppressant medication, organ transplants, primary immunodeficiency, and human immunodeficiency virus infection. Results: In total, 8058 of 47 552 (16.9%) BSI episodes were associated with underlying immunosuppression. This proportion increased over time (rate ratio, 1.019 per year [95% confidence interval {CI}, 1.012–1.027], P < .001). Immunosuppression was associated with a higher degree of Enterococcus faecium (odds ratio [OR], 3.16 [95% CI, 2.63–3.78]) and Pseudomonas spp (OR, 2.51 [95% CI, 2.16–2.91]) etiology. Intrinsic cephalosporin resistance was more frequent in BSI episodes with underlying immunosuppression (OR, 1.45 [95% CI, 1.36–1.55]). The 30-day mortality rate was higher in BSI episodes with underlying immunosuppression, at 17.9% (1439/8044), compared to 12.5% (4880/39 089) in episodes without immunosuppression (OR, 1.54 [95% CI, 1.45–1.64]). Conclusions: This study provides an updated summary of etiology and outcomes in BSI associated with immunosuppression. Underlying immunosuppression is increasingly prevalent among patients with BSI and is associated with resistance to cephalosporins and increased short-term mortality. Clinical guidelines for the management of BSI in immunosuppressed patients are warranted.

  • Open Access

    Intravenous Immunoglobulin Treatment in Patients With Streptococcal Toxic Shock Syndrome in Southern Sweden: A Retrospective Population-Based Study

    by Olof Wullt, Charlotta Utbult, Erik Carlson, Oskar Ljungquist, Torgny Sunnerhagen, Anna Bläckberg, Gustav Torisson

    Background: Intravenous immunoglobulins (IVIGs) have been suggested as an adjunctive treatment in streptococcal toxic shock syndrome (STSS), but there are no conclusive trials. In southern Sweden, IVIG is routinely used in certain hospitals but not others. We hypothesized that this would resemble a natural experiment, and we aimed to evaluate the effect of IVIG in patients with STSS. Method: We conducted a population-based retrospective cohort study on STSS cases in southern Sweden from 2017 to 2024. The main exposure was any IVIG treatment, and the primary outcome was 30-day mortality. Cox regression was used, adjusted for lactate, Sequential Organ Failure Assessment score, Charlson Comorbidity Index, and concurrent clindamycin treatment. We modeled IVIG as a time-dependent variable to address immortal time bias. Results: In total, 106 patients fulfilled STSS criteria, of which 56 (53%) were treated with IVIG. Despite geographic differences, the IVIG group was younger and had fewer comorbidities but higher disease severity at baseline. Crude analysis suggested lower mortality in the IVIG group (hazard ratio, 0.69; 95% CI, .34–1.41). However, after adjusting for covariates and accounting for immortal time bias, the hazard ratio was estimated at 1.69 (95% CI, .66–4.30). Conclusions: Although our study included a large population of patients with STSS, our results were inconclusive regarding the effect of IVIG on 30-day mortality. This study highlights the risk of bias in observational studies in rare conditions. Prospective interventional studies are needed to determine the efficacy of IVIG in patients with STSS.

  • Open Access

    Modifiable risk factors for peritoneal dialysis-related infections - a population-based cohort study on risk factors and outcomes in South Sweden

    by Oskar Ljungquist, Marta Tobijaszewska, Gustav Torisson, Giedre Martus, Mårten Segelmark, Jonas Tverring

    Background: The risk of infection-related death is high in patients undergoing dialysis. This study aimed to identify the modifiable risk factors for PD-related infections in patients undergoing peritoneal dialysis.Methods: This was a population-based retrospective cohort study conducted in Skåne, South Sweden, which included all patients receiving peritoneal dialysis (PD) between 2011 and 2020. The primary outcome was PD-related peritonitis, and the secondary outcome was a composite of PD-related infections, that is, peritonitis, exit site, or tunnel infections. Time-to-event frailty models, unadjusted and adjusted for age at PD start, sex and Charleson comorbidity index, were used to investigate potentially modifiable risk factors for PD-related infections. Cox regression models were subsequently used to analyze the relationship between PD-related infection episodes and all-cause mortality during the study period.Results: In total, 545 patients were included in the study, of whom 212 (39%) patients had at least one episode of peritonitis during a median follow-up time of 1.6 years. We found that BMI ≥ 30 may be associated with a clinically relevant increased risk for PD-related infection (aHR 1.45, 95% CI 1.08-1.93, p-value 0.012, nevents = 486), but not for peritonitis alone (adjusted Hazard Ratio, aHR, 1.34, 95% CI 0.95- 1.91; p = 0.099; nevents = 365). Patients with >3 peritonitis episodes had an almost three-fold increased risk of all-cause mortality (aHR, 2.66; 95% CI 1.56-4.52, p < 0.001).Conclusion: We found that a BMI ≥ 30 may be a modifiable risk factor for peritoneal dialysis-related infections and that multiple episodes of infectious complications of peritoneal dialysis are associated with increased all-cause mortality.


  • Open Access

    Morganella morganii bloodstream infection affects the elderly in close contact with health care

    by Olof Karlbom, Torgny Sunnerhagen, Oskar Ljungquist


  • Open Access

    A population-based study of the appearances of enteric Campylobacter and non-typhoidal Salmonella infections on computed tomography

    by Oskar Ljungquist, Sophie Poijes, Torgny Sunnerhagen, Anna Bläckberg

    Swift identification and diagnosis of gastrointestinal infections are crucial for prompt treatment, prevention of complications, and reduction of the risk of hospital transmission. The radiological appearance on computed tomography could potentially provide important clues to the etiology of gastrointestinal infections. We aimed to describe features based on computed tomography of patients diagnosed with Campylobacter, Salmonella or Shigella infections in South Sweden. This was a retrospective observational population-based cohort study conducted between 2019 and 2022 in Skåne, southern Sweden, a region populated by 1.4 million people. Using data from the Department of Clinical Microbiology combined with data from the Department of Radiology, we identified all patients who underwent computed tomography of the abdomen CTA two days before and up to seven days after sampling due to the suspicion of Campylobacter, Salmonella or Shigella during the study period. A total of 215 CTAs scans performed on 213 patients during the study period were included in the study. The median age of included patients was 45 years (range 11-86 years), and 54% (114/213) of the patients were women. Of the 215 CTAs, 80% (n = 172) had been performed due to Campylobacter and 20% (n = 43) due to Salmonella enteritis. CTA was not performed for any individual diagnosed with Shigella during the study period. There were no statistically significant differences in the radiological presentation of Campylobacter and Salmonella infections. The most common location of Campylobacter and Salmonella infections was the cecum, followed by the ascending colon. Enteric wall edema, contrast loading of the affected mucosa, and enteric fat stranding are typical features of both infections. The CTA characteristics of Campylobacter and Salmonella are similar, and cannot be used to reliably differentiate between different infectious etiologies.

  • Open Access

    A Population-Based Study on the Incidence, Risk Factors, and Outcome of Salmonella Bloodstream Infections in South Sweden 2012–2022

    by L. Björklund, Y. Mattisson, A. Bläckberg, T. Sunnerhagen, O. Ljungquist

    Introduction Invasive infections caused by Salmonella are a significant global health concern. This population-based study aimed to comprehensively analyze invasive Salmonella infections in South Sweden, focusing on incidence, clinical presentation, risk factors, and outcomes. Methods This population-based observational cohort study, conducted from 2012 to 2022, included all patients with Salmonella bloodstream infections (BSI) in the Skåne region, South Sweden. A control group consisted of patients with positive stool cultures/PCR for Salmonella but without BSI. Data were collected following a predefined study protocol from medical records. Standardized statistical analyses assessed patient characteristics, clinical presentation, and outcomes. Results Between 2012 and 2022, 149 patients with SBSI were identified, with the majority having non-typhoidal Salmonella (NTS) infections (95%). A declining trend in the incidence of SBSI was observed, with the highest incidence in 2012 (1.5 per 100,000 person-years) and the lowest in 2020 (0.3 per 100,000 person-years). Patients with BSI were more likely to be older, have comorbidities, be immunosuppressed, and use proton pump inhibitors (PPIs). Additionally, patients with BSI presented with fewer gastrointestinal symptoms, had a higher respiratory rate, lower saturation, and higher SOFA scores, suggesting a more septic presentation. Patients with SBSI had significantly longer hospital stays and higher 30-day, 90-day, 180-day, and 365-day mortality rates compared to the control group. Conclusion Invasive Salmonella infections are rare in South Sweden. In a cohort of enteric and invasive Salmonella infection, the absence of classic gastroenteritis symptoms increases the risk of Salmonella bloodstream infection. This study highlights the importance of distinguishing between clinical presentations to guide appropriate treatment when Salmonella infection is suspected. The declining trend in incidence, particularly associated with international travel, necessitates further investigation to understand contributing factors.


  • Open Access

    A population-based study on the incidence and aetiology of infectious complications in peritoneal dialysis in South Sweden

    by Marta Tobijaszewska, Giedre Martus, Torgny Sunnerhagen, Mårten Segelmark, Oskar Ljungquist

    Background: Peritonitis is a major cause of morbidity in peritoneal dialysis (PD) and an independent risk factor for elevated all-cause mortality. The aims of this study were to report the incidence, trend, aetiology, and antimicrobial susceptibility of PD-associated peritonitis and catheter-related infections in South Sweden between 2011-2020.Methods: This population-based observational cohort study included all patients with PD between the years 2011-2020 in the county of Skane. Data was accessed through the Swedish Renal Registry and the Department of Clinical Microbiology in Lund. Definitions issued by the International Society for Peritoneal Dialysis were implemented to assess PD-associated infections.Results: Medical records of 675 paediatric and adult PD patients were eligible for inclusion. Of those, 208 (31%) were female and the median age was 67 years (range 0-91). The overall rate of PD-peritonitis was 0.38 episodes per year at risk. Out of 484 episodes of peritonitis, 61% (n = 295) were caused by Gram-positive bacteria. There were 289 occurrences of exit site infections, of which most (n = 152, 53%) were Gram-positive. Tunnel infections occurred in 16 episodes and were caused by S. aureus or P. aeruginosa. Among all isolates, 37 were of MRSE, four of ESBL-producing E. coli, and one of MRSA.Conclusion: The crude rate of PD-peritonitis was stable during the study period. Gram-positive bacteria dominated the microbial aetiology, and antibiotic resistance was limited. It is important to monitor the aetiology, incidence, and resistance rates in PD-associated infections, to base empirical antibiotic regimens and facilitate prevention.


  • Open Access

    A population-based study on the incidence, risk factors and outcome of Salmonella bloodstream infections in South Sweden 2012-2022

    by Lina Björklund, Ylva Mattisson, Anna Bläckberg, Torgny Sunnerhagen, Oskar Ljungquist

    Introduction: Invasive infections caused by Salmonella are a significant global health concern. This population-based study aimed to comprehensively analyze invasive Salmonella infections in South Sweden, focusing on incidence, clinical presentation, risk factors, and outcomes. Methods This population-based observational cohort study, conducted from 2012 to 2022, included all patients with Salmonella bloodstream infections (BSI) in the Skåne region, South of Sweden. A control group consisted of patients with positive stool cultures/PCR for Salmonella but without BSI. Data were collected following a predefined study protocol and systematically reviewed. Standardized statistical analyses assessed patient characteristics, clinical presentation, and outcomes. Results Between 2012 and 2022, 149 patients with Salmonella BSI were identified, with the majority having non-typhoidal Salmonella (NTS) infections (95%). A declining trend in the incidence of Salmonella BSI was observed, with the highest incidence in 2012 (1.5 per 100,000 person-years) and the lowest in 2020 (0.3 per 100,000 person-years). Patients with BSI were more likely to be older, have comorbidities, be immunosuppressed, and use proton pump inhibitors (PPIs). Additionally, BSI patients presented with fewer gastrointestinal symptoms, had a higher respiratory rate, lower saturation, and higher clinical scores, suggesting a more septic presentation. Salmonella BSI patients had significantly longer hospital stays and higher 30-day, 90-day, 180-day, and 365-day mortality rates compared to the control group. Conclusion Invasive Salmonella infections are rare but have a substantial impact on patients in South Sweden. The absence of classic gastroenteritis symptoms increases the risk of Salmonella bloodstream infection. This study highlights the importance of distinguishing between clinical presentations to guide appropriate treatment. The declining trend in incidence, particularly associated with international travel, necessitates further investigation to understand contributing factors.

  • Open Access

    Pivmecillinam with Amoxicillin/Clavulanic acid as step down oral therapy in febrile Urinary Tract Infections caused by ESBL-producing Enterobacterales (PACUTI)

    by Jonas Tverring, Emeli Månsson, Vigith Andrews, Oskar Ljungquist

    Background: Oral treatment alternatives for febrile urinary tract infections are limited in the era of increasing antimicrobial resistance. We aim to evaluate if the combination of pivmecillinam and amoxicillin/clavulanic acid is non-inferior to current alternatives for step-down therapy in adult patients with febrile urinary tract infection. Methods: We plan to perform an investigator-initiated non-inferiority trial. Adult hospitalised patients treated with 1–5 days of intravenous antibiotics for acute febrile urinary tract infection caused by extended spectrum beta-lactamase (ESBL) producing Enterobacterales will be randomised 1:1 to either control (7–10 days of either oral ciprofloxacin 500 mg twice daily or oral trimethoprim–sulfamethoxazole 800 mg/160 mg twice daily or intravenous ertapenem 1 g once daily, depending on sex, drug allergy, glomerular filtration rate and susceptibility testing) or intervention (10 days of pivmecillinam 400 mg three times daily and amoxicillin/clavulanic acid 500/125 mg three times daily). The primary outcome will be clinical cure 10 days (+/− 2 days) after antibiotic treatment completion. Clinical cure is defined as being alive with absence of fever and return to non-infected baseline of urinary tract symptoms without additional antibiotic treatment or re-hospitalisation (for urinary tract infection) based on a centralised allocation-blinded structured telephone interview. We plan to recruit 330 patients to achieve 90% power based on a sample size simulation analysis using a two-group comparison, one-sided alpha of 2.5%, an absolute non-inferiority margin of 10% and expecting 93% clinical cure rate and 10% loss to follow-up. The primary endpoint will be analysed using generalised estimated equations and reported as risk difference for both intention-to-treat and per protocol populations. Patients are planned to be recruited from at least 10 centres in Sweden from 2023 to 2026. Discussion: If the combination of pivmecillinam and amoxicillin/clavulanic acid is found to be non-inferior to the control drugs there are potential benefits in terms of tolerability, frequency of interactions, outpatient treatment, side effects, nosocomial infections and drive for further antimicrobial resistance compared to existing drugs. Trial registration: NCT05224401. Registered on February 4, 2022